Amei Schweigert1, Carmen Fischer1, Doris Mayr2, Dietrich von Schweinitz1, Roland Kappler1, Jochen Hubertus3. 1. Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Lindwurmstr. 4, 80337, Munich, Germany. 2. Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany. 3. Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Lindwurmstr. 4, 80337, Munich, Germany. jochen.hubertus@med.uni-muenchen.de.
Abstract
PURPOSE: The Wnt/β-catenin pathway is known to be crucial for the regulation of embryogenesis and cell differentiation, and its constitutive activation is associated with a wide range of malignancies. There are two major principles for an activated Wnt/β-catenin pathway. The first is caused by the failure of the destruction complex, mainly due to the decreased expression of the tumor suppressor gene adenomatous polyposis coli (APC); the second is the mutation of the β-catenin (CTNNB1) protein itself. Wilms tumors (WTs) are also thought to be malignancies with a high rate of Wnt/β-catenin pathway activation. The aim of this study was to analyze a large cohort of WT for activated Wnt/β-catenin pathway. METHODS: The transcription of axis inhibition protein 2 (AXIN2) and APC was analyzed by real-time PCR. Expression was compared with those in healthy renal tissues as a control. Methylation status of the APC promoter was measured by pyrosequencing and correlated with APC expression. Finally, the mutations of CTNNB1 itself were detected by Sanger sequencing. RESULTS: The analysis was done in a cohort of 103 WTs, treated in our institution. There was a significant overexpression of AXIN2 in WTs (P < 0.0001), with 33 (32 %) tumors showing higher expression (median + 3× SD) than normal kidney tissue. In contrast, the expression of APC as well as its promoter methylation did not differ from control (P = 0.78; P = 0.82). Finally, there were only seven (6.8 %) mutations detectable in CTNNB1, and five out of seven were seen in WTs with AXIN2 overexpression. CONCLUSION: The finding that AXIN2, one of the major Wnt target genes, is overexpressed in our cohort of WTs, is indicative for the activation of the Wnt/β-catenin pathway. However, neither the alteration of APC nor frequent CTNNB1 mutations were seen in our analyses. Therefore, other mechanisms might be responsible for the common activation of the Wnt/β-catenin pathway.
PURPOSE: The Wnt/β-catenin pathway is known to be crucial for the regulation of embryogenesis and cell differentiation, and its constitutive activation is associated with a wide range of malignancies. There are two major principles for an activated Wnt/β-catenin pathway. The first is caused by the failure of the destruction complex, mainly due to the decreased expression of the tumor suppressor gene adenomatous polyposis coli (APC); the second is the mutation of the β-catenin (CTNNB1) protein itself. Wilms tumors (WTs) are also thought to be malignancies with a high rate of Wnt/β-catenin pathway activation. The aim of this study was to analyze a large cohort of WT for activated Wnt/β-catenin pathway. METHODS: The transcription of axis inhibition protein 2 (AXIN2) and APC was analyzed by real-time PCR. Expression was compared with those in healthy renal tissues as a control. Methylation status of the APC promoter was measured by pyrosequencing and correlated with APC expression. Finally, the mutations of CTNNB1 itself were detected by Sanger sequencing. RESULTS: The analysis was done in a cohort of 103 WTs, treated in our institution. There was a significant overexpression of AXIN2 in WTs (P < 0.0001), with 33 (32 %) tumors showing higher expression (median + 3× SD) than normal kidney tissue. In contrast, the expression of APC as well as its promoter methylation did not differ from control (P = 0.78; P = 0.82). Finally, there were only seven (6.8 %) mutations detectable in CTNNB1, and five out of seven were seen in WTs with AXIN2 overexpression. CONCLUSION: The finding that AXIN2, one of the major Wnt target genes, is overexpressed in our cohort of WTs, is indicative for the activation of the Wnt/β-catenin pathway. However, neither the alteration of APC nor frequent CTNNB1 mutations were seen in our analyses. Therefore, other mechanisms might be responsible for the common activation of the Wnt/β-catenin pathway.
Authors: Jochen Hubertus; Martin Lacher; Marietta Rottenkolber; Josef Müller-Höcker; Michael Berger; Maximilian Stehr; Dietrich von Schweinitz; Roland Kappler Journal: Oncol Rep Date: 2010-12-20 Impact factor: 3.906
Authors: Aviva Presser Aiden; Miguel N Rivera; Esther Rheinbay; Manching Ku; Erik J Coffman; Thanh T Truong; Sara O Vargas; Eric S Lander; Daniel A Haber; Bradley E Bernstein Journal: Cell Stem Cell Date: 2010-06-04 Impact factor: 24.633
Authors: W S Park; R R Oh; J Y Park; S H Lee; M S Shin; Y S Kim; S Y Kim; H K Lee; P J Kim; S T Oh; N J Yoo; J Y Lee Journal: Cancer Res Date: 1999-09-01 Impact factor: 12.701
Authors: T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler Journal: Science Date: 1998-09-04 Impact factor: 47.728
Authors: Chi-Ming Li; Meirong Guo; Alain Borczuk; Charles A Powell; Michelle Wei; Harshwardhan M Thaker; Richard Friedman; Ulf Klein; Benjamin Tycko Journal: Am J Pathol Date: 2002-06 Impact factor: 4.307
Authors: Ferdinand Zitzmann; Doris Mayr; Michael Berger; Maximilian Stehr; Dietrich von Schweinitz; Roland Kappler; Jochen Hubertus Journal: Oncol Rep Date: 2014-02-11 Impact factor: 3.906
Authors: Daniela Perotti; Peter Hohenstein; Italia Bongarzone; Mariana Maschietto; Mark Weeks; Paolo Radice; Kathy Pritchard-Jones Journal: Mol Cancer Ther Date: 2013-11-20 Impact factor: 6.261